DBV Technologies (NASDAQ:DBVT) Research Coverage Started at StockNews.com

StockNews.com started coverage on shares of DBV Technologies (NASDAQ:DBVT) in a report issued on Monday morning. The firm issued a hold rating on the stock.

Several other brokerages have also issued reports on DBVT. JMP Securities reiterated a “market outperform” rating and issued a $10.00 target price on shares of DBV Technologies in a research report on Friday, January 10th. HC Wainwright upped their target price on shares of DBV Technologies from $25.00 to $35.00 and gave the stock a “buy” rating in a research report on Thursday, October 24th.

DBV Technologies Price Performance

DBVT opened at $4.12 on Monday. The company has a fifty day moving average price of $3.89 and a 200-day moving average price of $3.85. The firm has a market capitalization of $84.75 million, a P/E ratio of -0.92 and a beta of 0.67. DBV Technologies has a one year low of $2.20 and a one year high of $9.40.

DBV Technologies Company Profile

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.